Eclampsia. VI. Maternal-perinatal outcome in 254 consecutive cases.
During a 12-year period, 254 cases of eclampsia were managed at this center. Eighty patients (32%) did not have edema, 58 (23%) had "relative hypertension," and 49 (19%) did not have proteinuria at the time of convulsions. Eclampsia developed at less than or equal to 20 weeks in 6 patients and beyond 48 hours post partum in 40 (16%). Convulsions developed in 33 while they were receiving standard doses of magnesium sulfate for preeclampsia during or after birth, and subsequent seizures developed in 36 (14%) after magnesium sulfate therapy was started. There was one maternal death (0.4%) and morbidity was frequent (acute renal failure, 4.7%; pulmonary edema, 4.3%; cardiorespiratory arrest, 3.1%; and aspiration, 2%. The use of multiple drug therapy was associated with significant maternal and neonatal complications. The total perinatal mortality was 11.8%, with the majority of them related to either abruptio placentae or extreme prematurity. These findings emphasize the need for intensive monitoring of women with preeclampsia throughout hospitalization and underscore the importance of maternal stabilization before and during transfer.
Sibai
B M
BM
Department of Obstetrics and Gynecology, University of Tennessee, Memphis.
D000293:Adolescent; D000328:Adult; D004461:Eclampsia / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D005260:Female; D005313:Fetal Death / Q000209:etiology; D006801:Humans; D006973:Hypertension / Q000209:etiology; D007226:Infant Mortality; D007231:Infant, Newborn; D008278:Magnesium Sulfate / Q000627:therapeutic use; D011247:Pregnancy; D011256:Pregnancy Outcome; D011295:Prenatal Care; D012640:Seizures / Q000209:etiology
D008278:Magnesium Sulfate